MiNK Therapeutics Inc (INKT)

[iHub News]

MiNK Therapeutics shares jump 80% after C-Further partnership announcement

March 10, 2026 7:15 AM
IH Market News

MiNK Therapeutics (NASDAQ:INKT) shares climbed about 80% on Tuesday after the company revealed a collaboration with C-Further aimed at developing a PRAME-targeted iNKT cell therapy for pediatric cancers.

Under the agreement, the clinical-stage biopharmaceutical company will receive around $1.1 million in non-dilutive funding to help support IND-enabling development of its PRAME-TCR-iNKT program. The deal also grants MiNK a double-digit percentage of any future commercial revenues generated by the therapy.

The partnership will focus on advancing a T cell receptor-engineered invariant natural killer T cell therapy designed to target PRAME, a tumor-associated antigen found in several pediatric cancers, including sarcomas, acute myeloid leukemia and medulloblastoma. The initiative is among the first projects selected by C-Further, an international consortium dedicated to developing new pediatric oncology treatments.

MiNK’s iNKT platform is built as an allogeneic, off-the-shelf treatment derived from healthy donors, allowing the therapy to be produced in advance and administered without the need for HLA matching or lymphodepleting chemotherapy. MiNK will act as the primary industry partner in the collaboration, while researchers at the University of Southampton will carry out preclinical studies to assess the therapy’s safety and anti-tumor activity across pediatric cancer models.

The agreement is non-exclusive, enabling MiNK to continue progressing its iNKT platform independently in other cancer indications and partnerships. Funding under the collaboration will be released as specific scientific milestones are achieved, covering stages from preclinical candidate selection through translational development.

C-Further is supported by Cancer Research Horizons, LifeArc and Great Ormond Street Hospital Charity, with a mission to accelerate the development of immunotherapies for children facing cancers with limited treatment options.

MiNK Therapeutics stock price

Original: MiNK Therapeutics shares jump 80% after C-Further partnership announcement